Clinical trials in København S

Clinical research in København S is advancing acute cardiac care by evaluating early therapeutic interventions for heart attacks and their effects on heart function.

• Immediate versus delayed beta blocker administration after STEMI
• Role of ACE inhibitor therapy in post‑infarct remodeling
• Impact of SGLT2 inhibitor treatment on cardiac biomarkers
• Assessment of echocardiographic parameters in acute myocardial infarction

These studies aim to refine emergency protocols and improve long‑term outcomes for patients with cardiovascular emergencies.

A diverse portfolio of oncology trials in København S targets melanoma, breast, pancreatic and other solid tumours, exploring immunotherapy, targeted radioligand therapy and cellular approaches.

• Neoadjuvant pembrolizumab for stage IIb/c melanoma
• Conversion of triple‑negative breast cancer to ER‑positive disease
• Combination of 177Lu‑DOTA‑TATE with olaparib for somatostatin receptor‑positive tumours
• Autologous tumor‑infiltrating lymphocytes infusion for melanoma with liver metastases

The overarching goal is to personalize treatment, increase response rates, and expand therapeutic options for patients with aggressive cancers.

Ongoing investigations in København S focus on multiple sclerosis, comparing CD20‑targeted antibodies and exploring dosing strategies to sustain disease control.

• Non‑inferiority comparison of rituximab versus ocrelizumab in active MS
• Extended‑interval dosing of CD20‑depleting agents
• MRI‑based monitoring of new or enlarging T2 lesions
• Long‑term safety evaluation over five years

Findings aim to optimize therapeutic regimens and improve quality of life for individuals living with neuro‑inflammatory disease.

Research on temporomandibular joint disorders in København S compares minimally invasive techniques to reduce pain and restore jaw function.

• Efficacy of intra‑articular corticosteroid injection for TMJ arthritis
• Pain relief comparison with arthrocentesis
• Functional outcome assessment of mandibular mobility
• Patient‑reported quality of life after TMJ interventions

The trials seek to establish evidence‑based guidelines for managing TMJ pain and improving oral health outcomes.

A pilot study in København S examines metabolic side effects of antipsychotic treatment in youth, testing a GLP‑1 receptor agonist as an adjunct therapy.

• Feasibility of GLP‑1 receptor agonist treatment in antipsychotic‑treated adolescents
• Effect on body weight and metabolic parameters
• Integration with standard psychiatric care pathways
• Safety and tolerability in the pediatric population

Results could provide a novel strategy to mitigate obesity while preserving mental health benefits.